Head-To-Head Contrast: Zentek (NASDAQ:ZTEK) and Axe Compute (NASDAQ:AGPU)

Axe Compute (NASDAQ:AGPU) and Zentek (NASDAQ:ZTEK) are both small-cap technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.

Valuation & Earnings

This table compares Axe Compute and Zentek”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axe Compute	$120,000.00	1,054.69	-$233.10 million	($5.75)	-1.90
Zentek	$108,251.00	575.49	-$7.07 million	($0.07)	-7.03

Zentek has lower revenue, but higher earnings than Axe Compute. Zentek is trading at a lower price-to-earnings ratio than Axe Compute, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Axe Compute and Zentek’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Axe Compute	-7,769.61%	-1,606.56%	-355.39%
Zentek	-5,848.76%	-70.93%	-52.26%

Risk and Volatility

Axe Compute has a beta of 3.47, suggesting that its share price is 247% more volatile than the S&P 500. Comparatively, Zentek has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500.

Insider and Institutional Ownership

9.0% of Axe Compute shares are owned by institutional investors. Comparatively, 0.8% of Zentek shares are owned by institutional investors. 1.2% of Axe Compute shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for Axe Compute and Zentek, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axe Compute	1	0	0	0	1.00
Zentek	1	0	0	0	1.00

Summary

Axe Compute beats Zentek on 6 of the 11 factors compared between the two stocks.

About Axe Compute

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient’s body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.

About Zentek

Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds. It is also developing graphene oxide synthesis and graphene synthesis. In addition, the company owns 100% interest in the Albany graphite project located in Northern Ontario, Canada. The company was formerly known as ZEN Graphene Solutions Ltd. and changed its name to Zentek Ltd. in October 2021. Zentek Ltd. was incorporated in 2008 and is headquartered in Guelph, Canada.